Paul Melmeyer with the National Organization for Rare Disorders explains the provisions of the Orphan Drug Act, how it creates incentives for the development of new treatments and why patients living with rare diseases continue to support the law.
Paul Melmeyer with the National Organization for Rare Disorders explains the provisions of the Orphan Drug Act, how it creates incentives for the development of new treatments and why patients living with rare diseases continue to support the law.
You’ll receive updates about new resources, patient stories and insights, advocacy work, and alerts about patient-support events.
